CHEK2 and ovarian cancer: In 5018 patients with ovarian cancer, there were 4689 patients without germline alterations, 175 patients (3.5%) with germline BRCA1 alterations, 102 (2.0%) with germline BRCA2 alterations, 27 (0.5%) with germline ATM alterations, 12 (0.2%) with germline PALB2 alterations, and 13 (0.3%) with germline CHEK2 alterations.